Acylin is the first biotechnology company focused on developing inhibitors of cellular acylation, an enzymatic mechanism fundamental to the molecular pathology of cancer, metabolic disease and neurodegeneration. Acquired in 2014
Acylin is the first biotechnology company focused on developing inhibitors of cellular acylation, an enzymatic mechanism fundamental to the molecular pathology of cancer, metabolic disease and neurodegeneration. Acquired in 2014